Prescription patterns of psychotropic medications for the treatment of psychotic disorders in the largest mental health institutions of Uganda

Journal of Clinical Psychopharmacology

Volumn 34, Issue 5, 2014, Pages 571-576

  Rukat, Annika ^a   Musisi, Seggane ^b   Ströhle, Andreas ^a   Mundt, Adrian P ^c,d,e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^e UNIVERSIDAD SAN SEBASTIÁN   (Chile)

Author keywords

inpatients; pharmacoepidemiology; prescription patterns; psychosis; Uganda

Indexed keywords

AMITRIPTYLINE; CARBAMAZEPINE; CHLORPROMAZINE; DIAZEPAM; FLUOXETINE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; LITHIUM; PSYCHOTROPIC AGENT; TRIFLUOPERAZINE; TRIHEXYPHENIDYL; VALPROIC ACID;

ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; DEPRESSION; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HOSPITAL; MULTICENTER STUDY; PATIENT REFERRAL; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; UGANDA; UNSPECIFIED PSYCHOSIS; EPIDEMIOLOGY; PSYCHOTIC DISORDERS; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HOSPITALS, PSYCHIATRIC; HUMANS; MALE; PRACTICE PATTERNS, PHYSICIANS'; PSYCHOTIC DISORDERS; PSYCHOTROPIC DRUGS; UGANDA; YOUNG ADULT;

EID: 84907423524     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000166     Document Type: Article

References (30)

1. Worldbank. Uganda. Available at: http://data.worldbank.org/country/ uganda. Accessed March 28, 2013.
2. Kigozi F, Ssebunnya J, Kizza D, et al. An overview of Uganda's mental health care system: Results from an assessment using the World Health Organization's assessment instrument for mental health systems (WHO-AIMS). Int J Ment Health Syst. 2010;4:1.
3. Ndyanabangi S, Basangwa D, Lutakome J, et al. Uganda mental health country profile. Int Rev Psychiatry. 2004;16:54-62.
4. Bhana A, Petersen I, Baillie KL, et al. Implementing the World Health Report 2001 recommendations for integrating mental health into primary health care: A situation analysis of three African countries: Ghana, South Africa and Uganda. Int Rev Psychiatry. 2010;22: 599-610.
5. Ministry of HealthVGovernment of Uganda. Health Sector Strategic Plan III. Available at: http://www.health.go.ug/docs/HSSP-III-2010.pdf. Accessed September 15, 2013.
6. Rahimtoola H, Buurma H, Tijssen CC, et al. Incidence and determinants of antidepressant drug use in migraine patients. Int Clin Psychopharmacol. 2003;18:331-339.
7. James BO. Rapid tranquillization agents for severe behavioural disturbance: A survey of African psychiatrists' prescription patterns. Trop Doct. 2011;41:49-50.
8. Purgato M, Barbui C. What is the WHO essential medicines list? Epidemiol Psychiatr Sci. 2012;21:343-345.
9. World Health Organization. Model List of Essential Medicines, 18th list (April 2013). Available at: http://www.who.int/medicines/publications/ essentialmedicines/18th-EML-Final-web-8Jul13.pdf. Accessed July 07, 2013.
10. Mundt AP, Aichberger MC, Fakhriddinov S, et al. Prescription patterns of patients diagnosed with schizophrenia in mental hospitals in Tashkent/Uzbekistan and in four German cities. Pharmacoepidemiol Drug Saf. 2012;21:145-151.
11. Mundt A, Ströhle A, Heimann H, et al. Pharmacoepidemiology of patients hospitalized for somatoform disorders in psychiatric hospitals and departments. Pharmacoepidemiol Drug Saf. 2010;19:687-693.
12. Bender S, Grohmann R, Engel RR, et al. Severe adverse drug reactions in psychiatric inpatients treated with neuroleptics. Pharmacopsychiatry. 2004;37(suppl 1):46-53.
13. Degner D, Grohmann R, Kropp S, et al. Severe adverse drug reactions of antidepressants: Results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry. 2004;37(suppl 1):S39-S45.
14. Grohmann R, Engel RR, Geissler KH, et al. Psychotropic drug use in psychiatric inpatients: Recent trends and changes over time-data from the AMSP study. Pharmacopsychiatry. 2004;37(suppl 1):S27-S38.
15. Pratt N, Andersen M, Bergman U, et al. Multi-country rapid adverse drug event assessment: The Asian Pharmacoepidemiology Network (AsPEN) antipsychotic and acute hyperglycaemia study. Pharmacoepidemiol Drug Saf. 2013;22:915-924.
16. Christensen RO, Anokbonggo WW. Prescribing in hospital outpatient departments and rural health facilities in Uganda: Some clinical and educational implications. Dan Med Bull. 1990;37:375-377.
17. Raja S, Wood SK, de Menil V, et al. Mapping mental health finances in Ghana, Uganda, Sri Lanka, India and Lao PDR. Int J Ment Health Syst. 2010;4:11.
18. Patel V, Araya R, Chatterjee S, et al. Treatment and prevention of mental disorders in low-income and middle-income countries. Lancet. 2007;370:991-1005.
19. Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006;163:2080-2089.
20. Latimer E, Wynant W, Clark R, et al. Underprescribing of clozapine and unexplained variation in use across hospitals and regions in the Canadian province of Québec. Clin Schizophr Relat Psychoses. 2013;7:33-41.
21. Tumwikirize WA, Ogwal-Okeng JW, Vernby O, et al. Access and use of medicines information sources by physicians in public hospitals in Uganda: A cross-sectional survey. Afr Health Sci. 2008;8:220-226.
22. Abbo C, Ekblad S,Waako P, et al. The prevalence and severity of mental illnesses handled by traditional healers in two districts in Uganda. Afr Health Sci. 2009;9(suppl 1):S16-S22.
23. Remick RA. Antidepressants: Which one? Can Fam Physician. 1986;32:587-592.
24. Ministry of HealthVGovernment of Uganda. Essential Medicines List for Uganda. Available at: http://www.who.int/selection-medicines/country-lists/uga- eml-2007.pdf. Accessed September 15, 2013.
25. Mundt AP, Fakhriddinov S, Fayzirahmanova M, et al. Use of psychiatric inpatient capacities and diagnostic practice in Tashkent/Uzbekistan as compared to Berlin/Germany. Soc Psychiatry Psychiatr Epidemiol. 2011;46:1295-1302.
26. Mundt A, Heinz A, Ströhle A. Uzbekistan: Psychiatry in transition. Eur Psychiatry. 2009;24:526-528.
27. Grimm SW, Richtand NM, Winter HR, et al. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol. 2006;61:58-69.
28. Trivedi JK, Sareen H, Yadav VS, et al. Prescription pattern of mood stabilizers for bipolar disorder at a tertiary health care centre in north India. Indian J Psychiatry. 2013;55:131-134.
29. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet. 2008;371:1085-1097.
30. Birkhimer LJ, Curtis JL, Jann MW. Use of carbamazepine in psychiatric disorders. Clin Pharm. 1985;4:425-434.